表紙
市場調査レポート

世界のコンパニオン診断市場:技術別(ポリメラーゼ連鎖反応、in-situハイブリダイゼーション、免疫組織化学)、用途別(乳がん、肺がん)、エンドユーザー別(製薬会社、参照試験所)市場のトレンドと予測

Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019

発行 MarketsandMarkets 商品コード 312600
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
世界のコンパニオン診断市場:技術別(ポリメラーゼ連鎖反応、in-situハイブリダイゼーション、免疫組織化学)、用途別(乳がん、肺がん)、エンドユーザー別(製薬会社、参照試験所)市場のトレンドと予測 Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019
出版日: 2014年09月08日 ページ情報: 英文 137 Pages
概要

コンパニオン診断の市場は、がんなどの個別化治療やテーラーメードの医薬品に対するニーズの高まり、製薬会社やバイオテクノロジー企業、参照試験所などのエンドユーザーによるコンパニオン診断テストの導入といった要因に後押しされる形で成長を続けており、米食品医薬品局(FDA)や欧州医薬品庁(EMA)なども医薬品開発の早期段階でコンパニオン診断テストを開発するよう促しています。その一方で、地域によって大きく異なる医療費償還基準、保険請求コード、技術評価手続き、未承認の自家調整試験(LDT)など、成長の妨げとなる要因も少なくありません。しかしコンパニオン診断は、神経学的疾患や感染症などへの応用が期待されており、次世代シーケンシング(NGS)をベースにしたコンパニオン診断の実用化やバイオインフォマティクス分野の発展なども見込めることから、今後も着実に成長していくと予想されます。世界のコンパニオン診断市場は、2014年の31億3,690万ドルから2019年には87億3,070万ドルへと拡大する見通しであり、この間の年平均成長率(CAGR)は22.7%になります。

当レポートは、世界のコンパニオン診断市場に光を当て、業界のトレンドなどを明らかにしたもので、用途別、技術別、エンドユーザー別、地域別の市場分析に加え、競合状況や主要企業のプロファイルも網羅しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブ・サマリー

第4章 主な分析結果

第5章 市場概要

  • イントロダクション
  • 進化
  • 市場区分
  • 市場の力学
    • 成長促進要因
    • 成長阻害要因
    • ビジネスチャンス
    • NGSなど市場の成長を促す各種の新技術

第6章 業界のトレンド

  • ポーターのファイブフォース分析
  • 戦略的ベンチマーキング

第7章 用途別の市場

  • イントロダクション
  • 乳がん
  • 肺がん
  • 結腸直腸がん
  • 黒色腫
  • 胃がん
  • 他の適応症(前立腺がん、卵巣がん、白血病、感染症、神経学的疾患)

第8章 技術別の市場

  • イントロダクション
  • ポリメラーゼ連鎖反応(PCR)
  • in-situハイブリダイゼーション(ISH)
  • 免疫組織化学(IHC)
  • 他の技術(NGS、多重アッセイ、細胞免疫テスト、モノクローナル抗体)

第9章 エンドユーザー別の市場

  • イントロダクション
  • 製薬会社
  • 参照試験所
  • その他(医薬品開発業務受託機関(CRO)、医師、病院、大学医療センター)

第10章 地域別の市場

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • 他の地域

第11章 競合状況

  • 概要
  • 協定、提携、協力
  • 合併と買収
  • 新製品発表
  • 事業拡大

第12章 主要企業のプロファイル

  • イントロダクション
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Biomerieux
  • Biogenex Laboratories
  • Danaher Corporation
  • Ge Healthcare
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific, Inc.

図表リスト

目次
Product Code: BT 2698

The global companion diagnostics market is expected to grow at a CAGR of 22.7% from 2014 to 2019. Factors such as rising need for personalized medicine in cancer treatment, growing adoption of companion diagnostics by the pharmaceutical industry, support from regulatory authorities, and emerging technologies such as next-generation sequencing (NGS) are expected to boost the global companion diagnostics market.

Among technologies, PCR is the most preferred test in the companion diagnostics market, which accounted for a share of 65.5% in 2014. This large share can be attributed to its ease of use, better results, faster turnaround time, and cost-effective solutions. The companion diagnostics market is expected to gain a larger market share in neurology and new oncology applications (leukemia, prostate cancer, and ovarian cancer) due to its efficient detection of biomarkers. Moreover, with the advancement in the bioinformatics field, NGS-based tests have the capability to target multiple genomes simultaneously and are likely to take over the existing technologies in the companion diagnostics market. The need for personalized medicine is increasing and it has gained importance in the research and medical centers, hospitals, and CROs. In the coming years, Asia is expected to be the key growth area in this market.

However, growth of this market is hampered by the non-validated home brew tests that account for a large market share due to its low costs and minimal approval procedures. Moreover, uncertain reimbursement and coverage policies restrict the growth of the global companion diagnostic market, thus limiting the commercialization process.

Reasons to Buy the Report

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios of the top players in the companion diagnostics market. The report analyzes the companion diagnostics market by technology, application, end-user, and geography
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the companion diagnostics market
  • Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the companion diagnostics market
  • Market Development: Comprehensive information about the emerging markets. The report analyzes the market for various companion diagnostics tests/kits across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the companion diagnostics market

Table of Contents

1 Introduction

  • 1.1 Objectives Of The Study
  • 1.2 Markets Covered
  • 1.3 Stakeholders
  • 1.4 Market Scope

2 Research Methodology

  • 2.1 Market Size Estimation
  • 2.2 Market Share Estimation
    • 2.2.1 Key Data Taken From Secondary Sources
    • 2.2.2 Key Data From Primary Sources
    • 2.2.3 Key Industry Insights
    • 2.2.4 Assumptions

3 Executive Summary

4 Premium Insights

5 Market Overview

  • 5.1 Introduction
  • 5.2 Evolution
  • 5.3 Market Segmentation
    • 5.3.1 Companion Diagnostics Market
  • 5.4 Market Dynamics
    • 5.4.1 Market Drivers
      • 5.4.1.1 Regulatory Bodies Encouraging Implementation Of Companion Diagnostics
      • 5.4.1.2 Rising Demand For Targeted Cancer Treatment & Tailored Drugs Ensure Robust Market Growth In Companion Diagnostic Tests
      • 5.4.1.3 Growing Adoption Of Companion Diagnostics By Pharmaceutical Companies & Reference Laboratories To Boost The Market
    • 5.4.2 Market Restraints
      • 5.4.2.1 Reimbursement Scenarios In Different Regions Hamper The Companion Diagnostic Market Growth
      • 5.4.2.2 Laboratory Developed Tests (Home Brew Tests) Affect Adoption Of Companion Diagnostic Tests
    • 5.4.3 Market Opportunities
    • 5.4.3.1 Emerging Technologies Such As Next-Generation Sequencing (NGS) Likely To Stimulate The Market
      • 5.4.3.2 Increasing Scope For Companion Diagnostics In Other Cancer Indications (Ovarian, Leukemia, Prostate) & Neurology

6 Industry Trends

  • 6.1 Porter's Five Forces Analysis
    • 6.1.1 Threat From New Entrants
    • 6.1.2 Threat From Substitutes
    • 6.1.3 Bargaining Power Of Suppliers
    • 6.1.4 Bargaining Power Of Buyers
    • 6.1.5 Intensity Of Competitive Rivalry
  • 6.2 Strategic Benchmarking

7 Global Companion Diagnostics Market, By Applications

  • 7.1 Introduction
  • 7.2 Breast Cancer
  • 7.3 Lung Cancer
  • 7.4 Colorectal Cancer
  • 7.5 Melanoma
  • 7.6 Gastric Cancer
  • 7.7 Other Indications (Prostate, Ovarian, Leukemia, Infectious Disease & Neurology)

8 Global Companion Diagnostics Market, By Technology

  • 8.1 Introduction
  • 8.2 Polymerase Chain Reaction (PCR)
  • 8.3 In Situ Hybridization (ISH)
  • 8.4 Immunohistochemistry (IHC)
  • 8.5 Other Technologies (NGS,Multiplex Assay, Cellular Immune Testing, Mab)

9 Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
    • 9.2.1 Companion Diagnostics Help To Reduce Cost & Aid In Faster Fda Clearance
    • 9.2.2 Accurate Identification & Recruitment Of Participants In Clinical Trials
    • 9.2.3 Pharmaceutical Companies Are Undergoing Partnerships & Collaborations With Companion Diagnostics Manufacturers
    • 9.2.4 Breast Cancer & Non-Small Cell Lung Cancer (NSCLC) Are The Major Focus Areas For Pharmaceutical Companies
    • 9.2.5 Payors Have Identified The Benefits Of Companion Diagnostics In Near Future
    • 9.2.6 Regulatory Agencies Encourage Drug Makers To Adopt Companion Diagnostics Test
  • 9.3 Reference Lab
    • 9.3.1 Importance Of Reference Laboratries In Global Market
  • 9.4 Others (Cro, Physicians, Hospitals & Academic Medical Centers)

10 Global Companion Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 Key Players Focusing On Companion Diagnostics For Breast And Lung Cancer
    • 10.2.2 Fda Initiatives In The U.S. To Encourage Significant Adoption Of Companion Diagnostics
    • 10.2.3 Adoption Of Pay-For-Performance Program Stimulates Payors To Reimburse For Companion Diagnostic Tests
    • 10.2.4 Focus On Personalized Medicine Is A Major Driver For Companion Diagnostics
  • 10.3 Europe
    • 10.3.1 Ema Supports The Development Of Companion Diagnostic Tests
    • 10.3.2 Rising Incidence Of Breast Cancer In Europe
    • 10.3.3 Fragmented Reimbursement Policy In Europe Hindering In Vitro Diagnostic Manufacturers From Investing In Companion Diagnostic Tests
  • 10.4 Asia
  • 10.5 Rest Of The W0rld

11 Competitive Landscape

  • 11.1 Overview
  • 11.2 Agreements, Partnerships & Collaborations
  • 11.3 Merger And Acquisitions
  • 11.4 New Product Launches
  • 11.5 Expansion

12 Company Profiles

  • 12.1 Introduction
  • 12.2 Abbott Laboratories, Inc.
  • 12.3 Agilent Technologies, Inc.
  • 12.4 Biomérieux
  • 12.5 Biogenex Laboratories
  • 12.6 Danaher Corporation
  • 12.7 Ge Healthcare
  • 12.8 Myriad Genetics, Inc.
  • 12.9 Qiagen N.V.
  • 12.10 Roche Diagnostics
  • 12.11 Thermo Fisher Scientific, Inc.

List of Tables

  • Table 1 Increasing Need For Targeted Treatment In Oncology Is Propelling The Global arket
  • Table 2 Reimbursement Issues Hamper Growth Of Market
  • Table 3 Advanced Technologies Likely To Stimulate Market Growth
  • Table 1 Global Market, By Applications, 2012-2019 ($Million) 44
  • Table 2 Breast Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 45
  • Table 3 Lung Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 49
  • Table 4 Colorectal Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million)
  • Table 5 Melanoma Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 52
  • Table 6 Gastric Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 53
  • Table 7 Other Indications Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 54
  • Table 8 Global Companion Diagnostics Market Size, By Technology, 2012-2019 ($Million) 57
  • Table 9 Market Size For Polymerase Chain Reaction, By Geography, 2012-2019 ($Million) 58
  • Table 10 Market Size For In Situ Hybridization, By Geography, 2012-2019 ($Million) 60
  • Table 11 Market Size For Immunohistochemistry, By Geography, 2012-2019 ($Million) 61
  • Table 12 Market Size For Other Technologies, By Geography, 2012-2019 ($Million) 63
  • Table 13 Global Companion Diagnostics Market, By End-Users, 2014-2019 ($Million) 66
  • Table 14 Pharmaceutical Companies Companion Diagnostics Market, By Geography, 2014-2019 ($Million) 68
  • Table 15 Reference Laboratories Companion Diagnostics Market, By Geography, 2014-2019 ($Million) 71
  • Table 16 Other End Users Companion Diagnostics Market, By Geography, 2014-2019 ($Million) 73
  • Table 17 Companion Diagnostics Market Size, By Geography, 2012-2019 ($Million) 76
  • Table 18 North America: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million)
  • Table 19 North America: Market Size, By End User, 2012-2019 ($Million) 82
  • Table 20 North America: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 21 North America: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 22 North America: Market Size For Other End Users, By Application, 2012-2019 ($Million)
  • Table 23 North America: Market Size, By Technology, 2012-2019 ($Million)
  • Table 24 North America: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 25 North America: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 26 North America: Market Size For Other End Users, By Technology, 2012-2019 ($Million)
  • Table 27 Europe: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million) 88
  • Table 28 Europe: Market Size, By End User, 2012-2019 ($Million) 90
  • Table 29 Europe: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 30 Europe: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 31 Europe: Market Size For Other End Users, By Application, 2012-2019 ($Million) 91
  • Table 32 Europe: Market Size, By Technology, 2012-2019 ($Million) 91
  • Table 33 Europe: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 34 Europe: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 35 Europe: Market Size For Other End Users, By Technology, 2012-2019 ($Million) 92
  • Table 36 Asia: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million) 95
  • Table 37 Asia: Market Size, By End Users, 2012-2019 ($Million) 95
  • Table 38 Asia: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 39 Asia: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 40 Asia: Market Size For Other End Users, By Application, 2012-2019 ($Million) 96
  • Table 41 Asia: Market Size, By Technology, 2012-2019 ($Million) 97
  • Table 42 Asia: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 43 Asia: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 44 Asia: Market Size For Other End Users, By Technology, 2012-2019 ($Million) 98
  • Table 45 Row: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million) 99
  • Table 46 Row: Market Size, By End User, 2012-2019 ($Million) 99
  • Table 47 Row: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 48 Row: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 49 Row: Market Size For Other End Users, By Application, 2012-2019 ($Million) 101
  • Table 50 Row: Market Size, By Technology, 2012-2019 ($Million) 101
  • Table 51 Row: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 52 Row: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 53 Row: Market Size For Other End Users, By Technology, 2012-2019 ($Million) 102
  • Table 54 Agreements, Partnerships & Collaborations, 2011-2014
  • Table 55 Merger And Acquisitions, 2011-2014
  • Table 56 New Product Launch, 2011-2014
  • Table 57 Expansion, 2011-2014

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Bottom-Up Approach
  • Figure 3 Top-Down Approach
  • Figure 4 Break Down Of Primary Interviews: By Company Type, Designation, And Region
  • Figure 5 Cdx Technology Market Snapshot(2014 Vs 2019) : Ngs Market In Other Technology Is Expected To Grow Aggresively In Next Five Years.
  • Figure 6 Global Companion Diagnostics Market,By Application,2014
  • Figure 7 Market Share,2014
  • Figure 1 Attractive Market Opportunities In Global Market
  • Figure 2 Breast Cancer Segment Hold The Largest Market Share In Global Companion Diagnostic Market
  • Figure 3 Asia Is Expected To Commands Larger Share In Global Market
  • Figure 4 Global Companion Diagnostic Market, By Geography, 2014-2019
  • Figure 5 Global Companion Diagnostic Market, By Technology(2014-2019)
  • Figure 6 Asia Is Expected To Enter Exponential Growth Phase Market In Next 5 Years
  • Figure 7 New Approches Adopted By Leading Players
  • Figure 8 Technology Advancement Plays An Important Role In The Companion Diagnostic Market.
  • Figure 9 Market Segmentation :By Technology,Application And End-Users
  • Figure 10 Companion Diagnostic Gained Increasing Demand In The Oncology Segment
  • Figure 11 Porter's Five Forces Analysis
  • Figure 12 Strategic Benchmarking: Roche And Agilent Technologies, Inc. Largely Adopted Inorganic Growth Strategies For Technology Integration And Product Enhancement
  • Figure 13 Companion Diagnostics Applications Market Will Be Driven By Lung & Breast Cancer
  • Figure 14 Breast Cancer
  • Figure 15 Melanoma
  • Figure 16 End Users Of Companion Diagnostic Market
  • Figure 17 The Adoption Of Companion Diagnostic Is Significantly Growing Among Pharmaceutical Firms And Reference Laboratories
  • Figure 18 Pharmaceutical Companies In North America:Major End User Of Companion Diagnostic
  • Figure 19 Asia Is Expected To Be The Fastest-Growing Market For Companion Diagnostic
  • Figure 20 North America Driving The Global Market
  • Figure 21 Risingprevalence Of Life-Threatening Diseases To Drive Market Growth In North America
  • Figure 22 Europe Commands One-Third Of The Global Market
  • Figure 23 Companies Adopted Collaborations/Partnerships/Agreements As The Key Growth Strategy Over The Last Three Years
  • Figure 24 Battle For Market Share: Partnerships, Collaborations, Agreements Were Preferred Strategies
  • Figure 25 Geographic Revenue Mix Of Top 5 Market Players - Reference
  • Figure 26 Abbott Laboratories, Inc.: Business Overview
  • Figure 27 Agilent Technologies, Inc.: Business Overview
  • Figure 28 Swot Analysis
  • Figure 29 Biomeriux : Business Overview
  • Figure 30 Danaher Corporation : Business Overview
  • Figure 31 Ge Healthcare : Business Overview
  • Figure 32 Myriad Genetics : Business Overview
  • Figure 33 Qiagen N.V. : Business Overview
  • Figure 34 Swot Analysis
  • Figure 35 Roche Diagnostics: Business Overview
  • Figure 36 Thermo Fisher Scientific : Business Overview
Back to Top